Impact of incretin hormones on β-cell function in subjects with normal or impaired glucose tolerance
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The mechanisms by which the enteroinsular axis influences β-cell function have not been investigated in detail. We performed oral and isoglycemic intravenous (IV) glucose administration in subjects with normal (NGT; n = 11) or impaired glucose tolerance (IGT; n = 10), using C-peptide deconvolution to calculate insulin secretion rates and mathematical modeling to quantitate β-cell function. The incretin effect was taken to be the ratio of oral to IV responses. In NGT, incretin-mediated insulin release [oral glucose tolerance test (OGTT)/IV ratio = 1.59 ± 0.18, P = 0.004] amounted to 18 ± 2 nmol/m 2 (32 ± 4% of oral response), and its time course matched that of total insulin secretion. The β-cell glucose sensitivity (OGTT/IV ratio = 1.52 ± 0.26, P = 0.02), rate sensitivity (response to glucose rate of change, OGTT/IV ratio = 2.22 ± 0.37, P = 0.06), and glucose-independent potentiation were markedly higher with oral than IV glucose. In IGT, β-cell glucose sensitivity (75 ± 14 vs. 156 ± 28 pmol·min−1·m−2·mM−1 of NGT, P = 0.01) and potentiation were impaired on the OGTT. The incretin effect was not significantly different from NGT in terms of plasma glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide responses, total insulin secretion, and enhancement of β-cell glucose sensitivity (OGTT/IV ratio = 1.73 ± 0.24, P = NS vs. NGT). However, the time courses of incretin-mediated insulin secretion and potentiation were altered, with a predominance of glucose-induced vs. incretin-mediated stimulation. We conclude that, under physiological circumstances, incretin-mediated stimulation of insulin secretion results from an enhancement of all dynamic aspects of β-cell function, particularly β-cell glucose sensitivity. In IGT, β-cell function is inherently impaired, whereas the incretin effect is only partially affected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 5×
“It is important to emphasize that the contribution of incretin-mediated secretion to total secretion is a function of the oral load: in NGT individuals, larger glucose loads (or mixed meals) will cause greater insulin release without altering the plasma glucose profile, thereby amplifying the role of incretin hormones…”
BackgroundMethodInfluentialThe Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion
MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590 · cited 1×
“There is evidence that most of the incretin effect is due to the gut-derived incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), secreted by L and K cells, respectively, in the jejunum, ileum, and colon, which enhance glucose-dependent insulin secretion by binding…”
BackgroundThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582 · cited 2×
“GLP-1 secretion is reduced in patients with type 2 diabetes both after an oral glucose load (40) and during a meal test compared with lean or obese nondiabetic subjects (43), whereas stimulation of insulin secretion by acute or extended GLP-1 infusions is relatively well preserved in diabetic patients (18, 35).”
BackgroundSelf-citationImpaired Glucose Tolerance as a Disorder of Insulin Action
Lillioja, S., Mott, D. M., Howard, B. V., Bennett, P. H., Yki-Järvinen, H., Freymond, D., Nyomba, B. L., Zurlo, F., Swinburn, B., & Bogardus, C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181901 · Cited by 578 · cited 1×
“IGT subjects frequently are insulin resistant (19) and display similar defects in -cell function as overtly diabetic patients, only of a lesser degree (9, 10, 34).”
BackgroundFerrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540 · cited 2×
“IGT subjects frequently are insulin resistant (19) and display similar defects in -cell function as overtly diabetic patients, only of a lesser degree (9, 10, 34).”
BackgroundSelf-citationVilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528 · cited 1×
“GLP-1 secretion is reduced in patients with type 2 diabetes both after an oral glucose load (40) and during a meal test compared with lean or obese nondiabetic subjects (43), whereas stimulation of insulin secretion by acute or extended GLP-1 infusions is relatively well preserved in diabetic patients (18, 35).”
BackgroundSelf-citationVilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Self-citationNauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.020 · Cited by 137 · cited 2×
“Previous estimates of incretin-mediated insulin release have been larger (29), but they were based on plasma insulin concentrations rather than insulin secretion rates.”
BackgroundSelf-citationToffolo, G., Breda, E., Cavaghan, M. K., Ehrmann, D. A., Polonsky, K. S., & Cobelli, C. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.1.e2 · Cited by 112 · cited 1×
“This “glucose memory” effect has been previously quantitated with repeated IV glucose infusions (38) but not with a glucose profile simulating the OGTT.”
BackgroundQuddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111 · cited 2×
“GLP-1 secretion is reduced in patients with type 2 diabetes both after an oral glucose load (40) and during a meal test compared with lean or obese nondiabetic subjects (43), whereas stimulation of insulin secretion by acute or extended GLP-1 infusions is relatively well preserved in diabetic patients (18, 35).”
Background
Cited by
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409
Self-citationReduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349
Self-citationRosenstock, J., Foley, J. E., Rendell, M., Landin-Olsson, M., Holst, J. J., Deacon, C. F., Rochotte, E., & Baron, M. A. (2008) · Diabetes Care · doi:10.2337/dc07-1616 · Cited by 153
Self-citationEvaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Self-citationβ‐cell function assessment from modelling of oral tests: an effective approach
Mari, A., & Ferrannini, E. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00946.x · Cited by 112
Self-citation
Metadata
- Authors
- Muscelli, E., Mari, A., Natali, A., Astiarraga, B. D., Camastra, S., Frascerra, S., Holst, J. J., & Ferrannini, E.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2006-12
- Volume
- 291
- Issue
- 6
- Pages
- E1144-E1150
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2124489205
- Cited by
- 87
- References
- 12
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of incretin hormones on β-cell function in subjects with normal or impaired glucose tolerance. https://app.cochat.ai/papers/10.1152/ajpendo.00571.2005
- The paper
- Muscelli, E., Mari, A., Natali, A., Astiarraga, B. D., Camastra, S., Frascerra, S., Holst, J. J., & Ferrannini, E. (2006). Impact of incretin hormones on β-cell function in subjects with normal or impaired glucose tolerance. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00571.2005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.